These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2188925)

  • 1. Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Karanes C; Crowley J; Sawkar L; Tranum BL; Hicks WJ; Bonnet JD; Dabich L; Dana BW; Salmon S
    Invest New Drugs; 1990 Feb; 8(1):101-4. PubMed ID: 2188925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
    Earhart RH; Amato DJ; Chang AY; Borden EC; Shiraki M; Dowd ME; Comis RL; Davis TE; Smith TJ
    Invest New Drugs; 1990 Feb; 8(1):113-9. PubMed ID: 2188926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aclarubicin in advanced thyroid cancer: a phase II study.
    Samonigg H; Hossfeld DK; Spehn J; Fill H; Leb G
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1271-5. PubMed ID: 3181249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aclarubicin in the treatment of multiple myeloma.
    Sezaki T; Adachi T; Ishii H; Asano K; Takahashi I; Kimura I
    Jpn J Clin Oncol; 1984 Sep; 14(3):353-8. PubMed ID: 6384577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A clinical study of the radiosensitization of aclarubicin].
    Miyamoto T; Morita S; Asakawa H; Koyama T; Dokiya T; Kondo M; Yamashita T; Ohkawa T; Kanehira T
    Gan No Rinsho; 1989 Mar; 35(4):472-6. PubMed ID: 2654441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
    Kraut EH; Crowley JJ; Grever MR; Keppen MD; Bonnet JD; Hynes HE; Salmon SE
    Invest New Drugs; 1990 May; 8(2):199-200. PubMed ID: 1696569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma.
    Martino S; Decker DA; Hynes HE; Kresge CL
    Invest New Drugs; 1987 Dec; 5(4):373-4. PubMed ID: 3481362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
    Edelstein MB; Crowley JJ; Valeriote FA; Bonnet JD; Carden JO; Khanna RC; Salmon SE; Ungerleider JS
    Invest New Drugs; 1990; 8 Suppl 1():S83-6. PubMed ID: 2380019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of aclacinomycin-A in patients with adenocarcinoma and large cell carcinoma of the lung.
    Tapazoglou E; Haas CD; Samson MK; Baker LH; Pazdur R
    Am J Clin Oncol; 1985 Aug; 8(4):298-301. PubMed ID: 3002165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of aclacinomycin A (ACM-A, NSC208734) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey G
    Am J Clin Oncol; 1983 Apr; 6(2):187-90. PubMed ID: 6572470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
    Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
    Casper ES; Gralla RJ; Young CW
    Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study.
    Kerpel-Fronius S; Gyergyay F; Hindy I; Decker A; Sawinsky I; Fäller K; Mechl Z; Nekulova M; Kolaric K; Tomek R
    Oncology; 1987; 44(3):159-63. PubMed ID: 3474571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP; Silberman H; Bartolucci AA
    Cancer Treat Rep; 1987; 71(7-8):773-4. PubMed ID: 3300970
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple myeloma treated with high dose intravenous melphalan.
    Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
    Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.